The abstract mentions patient-specific disease courses were concordant with trajectories of MB-FUS-enriched plasma cell-free DNA but provides no mechanistic explanation. Understanding this relationship could reveal biomarkers for treatment response or disease monitoring. Gap type: unexplained_observation Source paper: Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial. (2025, The Lancet. Oncology, PMID:41308679)
Landscape Summary: What explains the concordance between MB-FUS-enriched plasma cfDNA and disease trajectories? is a 0.75 priority gap in neuro-oncology. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What explains the concordance between MB-FUS-enriched plasma cfDNA and disease trajectories? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: